Fig. 11

The NRP2 associated pathway is more determinant for the aggressiveness of mccRCC but not for triple negative breast cancers. Analysis of cbioportal database highlighted the relative levels of VEGFA (a), VEGFC (b), NRP1 (c) and NRP2 (d) mRNA in a panel of RCC (769 (769P), 786-O (786), ACHN (A), Caki1 (C1), Caki2 (C2), RCC10 (R10)) and TNBC (BT474 (BT), MDAMB231 (231), MDAMB134 (134), MDAMB436 (436), MDAMB468 (468)). Correlation between genes of the NRP1 and NRP2 pathways and survival (DFS/PFS/OS) in M0 and M1 RCC patients (e) and TNBC (f) patients. The tested genes of the NRP1 pathway were the following: NRP1 (N1), VEGFA, VEGFR1 (R1), VEGFR2 (R2), Semaphorin 3A (Sema3A), Plexin A1 (PLXNA1). The tested genes of the NRP2 pathway were the following: NRP2 (N1), VEGFC, VEGFR3 (R3), Semaphorin 3F (Sema3F), Plexin A2 (PLXNA1) and PROX1. The p-values of genes associated with shorter DFS/PFS/OS appear white on a black background; the p-values of genes associated with a longer DFS/PFS/OS appear black on a gray background. Significant p-values are given; a trend to significance is indicated by a “T”. Specific cut-off are indicated (First, second or third quartile (1°, 2°, 3° Q). A score was established as follows: a positive point was given for a gene with a trend to good prognosis; two positive points for a gene associated with good prognosis and with a significant p-value; a negative point was given for a gene with a trend to poor prognosis; two negative points were given for a gene associated with poor prognosis and with a significant p-value. Positive scores were obtained for DFS and OS of M0 RCC patients and the NRP2 pathway (respectively 4 and 6) and for the OS of M1 RCC patients and the NRP1 pathway (2). Negative scores were obtained for obtained for the DFS and OS of M0 and PFS of M1 RCC patients and the NRP1 pathway (respectively (− 1), (− 1) (− 6), for the PFS and OS of M1 RCC patients and the NRP2 pathway. Negative score were obtained for the NRP1 and NRP2 pathways for PFS and OS